| Symbol | UNCY |
|---|---|
| Name | UNICYCIVE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5150 EL CAMINO REAL,SUITE A-32, LOS ALTOS, California, 94022, United States |
| Telephone | +1 650 351-4495 |
| Fax | — |
| — | |
| Website | https://www.unicycive.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001766140 |
| Description | Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The companys lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycives other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Unicycive Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001213900-26-090075 <b>Size:</b> 14 KB
Read more(10% Negative) UNICYCIVE THERAPEUTICS, INC. (UNCY) Reports Q3 2026 Financial Results
Read moreUnicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Read moreUnicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Read moreNew Form 4/A - Unicycive Therapeutics, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001213900-26-082273 <b>Size:</b> 5 KB
Read moreNew Form 4/A - Unicycive Therapeutics, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001213900-26-082270 <b>Size:</b> 5 KB
Read moreSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Read more(99% Neutral) UNICYCIVE THERAPEUTICS, INC. (UNCY) Announces Update on Collaboration with Exchange
Read moreUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Read moreUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06218290 | A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With C… | Phase2 | Chronic Kidney Disease Requiring Chronic Dialysis | Completed | 2023-12-15 | 2024-05-29 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Oxylanthanum Carbonate | Other | Phase PHASE2 | Chronic Kidney Disease Requiring Chronic Dialysis | COMPLETED | NCT06218290 |
| Oxylanthanum Carbonate | DRUG | Phase PHASE2 | Chronic Kidney Disease Requiring Chronic Dialysis | COMPLETED | NCT06218290 |